Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts

IntroductionProteasome inhibition is an attractive approach to anticancer therapy and may have relevancy in breast cancer treatment. Natural products, such as dietary flavonoids, have been suggested as natural proteasome inhibitors with potential use for cancer prevention and therapeutics. We previously reported that apigenin, a flavonoid widely distributed in many fruits and vegetables, can inhibit proteasome activity and can induce apoptosis in cultured leukemia Jurkat T cells. Whether apigenin has proteasome-inhibitory activity in the highly metastatic human breast MDA-MB-231 cells and xenografts, however, is unknown.MethodsMDA-MB-231 breast cancer cell cultures and xenografts were treated with apigenin, followed by measurement of reduced cellular viability/proliferation, proteasome inhibition, and apoptosis induction. Inhibition of the proteasome was determined by levels of the proteasomal chymotrypsin-like activity, by ubiquitinated proteins, and by accumulation of proteasome target proteins in extracts of the treated cells or tumors. Apoptotic cell death was measured by capase-3/caspase-7 activation, poly(ADP-ribose) polymerase cleavage, and immunohistochemistry for terminal nucleotidyl transferase-mediated nick end labeling positivity.ResultsWe report for the first time that apigenin inhibits the proteasomal chymotrypsin-like activity and induces apoptosis not only in cultured MDA-MB-231 cells but also in MDA-MB-231 xenografts. Furthermore, while apigenin has antibreast tumor activity, no apparent toxicity to the tested animals was observed.ConclusionWe have shown that apigenin is an effective proteasome inhibitor in cultured breast cancer cells and in breast cancer xenografts. Furthermore, apigenin induces apoptotic cell death in human breast cancer cells and exhibits anticancer activities in tumors. The results suggest its potential benefits in breast cancer prevention and treatment.

[1]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[2]  Di Chen,et al.  The proteasome as a potential target for novel anticancer drugs and chemosensitizers. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[3]  C. Divgi,et al.  Current status of therapy of solid tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  JB Almond,et al.  The proteasome: a novel target for cancer chemotherapy , 2002, Leukemia.

[5]  K. Daniel,et al.  Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. , 2003, Progress in cell cycle research.

[6]  Di Chen,et al.  Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. , 2005, Biochemical pharmacology.

[7]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.

[8]  David M. Smith,et al.  Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo * , 2001, The Journal of Biological Chemistry.

[9]  Xianglin Shi,et al.  Apigenin Inhibits Expression of Vascular Endothelial Growth Factor and Angiogenesis in Human Lung Cancer Cells: Implication of Chemoprevention of Lung Cancer , 2005, Molecular Pharmacology.

[10]  Jae Woong Lee,et al.  Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast , 2007, Archives of pharmacal research.

[11]  Pei-Wen Zheng,et al.  Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. , 2005, Life sciences.

[12]  S. Shukla,et al.  Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft , 2006, Molecular Cancer Therapeutics.

[13]  J. Adams.  Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.

[14]  T. Shiraishi,et al.  The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor–related apoptosis-inducing ligand , 2006, Molecular Cancer Therapeutics.

[15]  Shishir Shishodia,et al.  Molecular targets of dietary agents for prevention and therapy of cancer. , 2006, Biochemical pharmacology.

[16]  Q. Dou,et al.  Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts , 1998, Cell Death and Differentiation.

[17]  Q Ping Dou,et al.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.

[18]  J. Kang,et al.  Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. , 2004, The Journal of nutrition.

[19]  P. Elliott,et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  H. Mukhtar,et al.  Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells , 2002, Oncogene.

[21]  A. Goldberg.  Functions of the proteasome: the lysis at the end of the tunnel. , 1995, Science.

[22]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[23]  Anil Mishra,et al.  Up‐regulation of insulin‐like growth factor binding protein‐3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Q. Dou,et al.  Proteasome inhibitors as potential novel anticancer agents. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  S. Shukla,et al.  Apigenin and cancer chemoprevention: progress, potential and promise (review). , 2007, International journal of oncology.

[26]  P. Pour,et al.  Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. , 1997, Anticancer research.

[27]  M. Borad,et al.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Di Chen,et al.  Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. , 2007, Frontiers in bioscience : a journal and virtual library.

[29]  J. Kang,et al.  Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. , 2004, The Journal of nutrition.

[30]  K. Anderson,et al.  Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. , 2006, Cancer research.

[31]  R. Huber,et al.  Structure of 20S proteasome from yeast at 2.4Å resolution , 1997, Nature.

[32]  Di Chen,et al.  Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. , 2005, Frontiers in bioscience : a journal and virtual library.